Grégory Catteau - Concepedia

Concepedia

Author

Grégory Catteau

GlaxoSmithKline (Belgium)

Also Known As

Gregory Catteau, Grégory Catteau

18

Publications

1.2K

Citations

13

H-Index

20

Concepts

All Affiliations

GlaxoSmithKline (Belgium)Stiftung Juliusspital GlaxoSmithKline (United States)Uppsala University Hospital Uppsala University

GC

About

Grégory Catteau is an author at GlaxoSmithKline (Belgium) specializing in medicine, vaccination, and human papillomavirus vaccines.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	136
2	Public Health	2	2	80
3	Immunology	2	2	80
4	Obstetrics	2	2	80
5	Cervical Cancer	2	2	80

Grégory Catteau

×

13

Publications

1.2K

Citations

13

H-Index

	Year	Citations
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Paulo Naud, Cecília Roteli-Martins, Newton Sérgio de Carvalho, Human Vaccines & Immunotherapeutics	2014	245
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson, Human Vaccines	2011	194
Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial Allan Hildesheim, Sholom Wacholder, Grégory Catteau, Vaccine	2014	130
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults Roman Chlíbek, Karlis Pauksens, Lars Rombo, Vaccine	2015	121
Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: <i>Post‐hoc</i> analysis from a randomized controlled trial Suzanne M. Garland, Jorma Paavonen, Unnop Jaisamrarn, International Journal of Cancer	2016	100
Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women Tiina Petäjä, Court Pedersen, Airi Põder, International Journal of Cancer	2010	91
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults Tino F. Schwarz, Stéphanie Volpe, Grégory Catteau, Human Vaccines & Immunotherapeutics	2018	78
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study Mark H. Einstein, Myron J. Levin, Archana Chatterjee, Human Vaccines & Immunotherapeutics	2014	59
Four-Year Follow-up of the Immunogenicity and Safety of the HPV-16/18 AS04-Adjuvanted Vaccine When Administered to Adolescent Girls Aged 10–14 Years Tino F. Schwarz, Li‐Min Huang, Doris Maribel Rivera Medina, Journal of Adolescent Health VaccinationVaccine SafetyHpv-16/18 As04-adjuvanted VaccineVaccine DevelopmentHuman Papillomavirus Vaccines	2012	56
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years Tino F. Schwarz, Marek Spaczyński, Achim Schneider, Human Vaccines ImmunologyGynecologyImmunotherapyCervical Cancer PreventionHuman Papillomavirus Vaccines	2011	42

Page 1